New contract a “significant win” for UK manufacturer
Cleveland, UK: Leading research peptide manufacturer, Cambridge Research Biochemicals (CRB) announced today that it has been appointed by RCUK Shared Services Centre Ltd (RCUK SSC Ltd) as a key supplier of custom synthesised peptides and custom generated polyclonal and monoclonal antibodies. The new two-year contract will enable CRB to build on its existing relationship with the Medical Research Council and other UK Research Councils and includes the option to extend it to higher education, charities and the wider public sector by agreement.
CRB Commercial Director, Emily Humphrys commented that the contract is a “significant win for CRB that validates our focus on quality and innovation in the production of speciality research peptides and antibodies. We are delighted to have been appointed and we will be expanding our production and client-handling teams to ensure that we continue to reach the high technical and service standards required by the Research Councils.”
Richard Fowles, Category Manager for RCUK SSC Ltd commented “CRB demonstrated a very high level of professionalism within their tender submission which demonstrated their strong commitment to the quality and ethical standards required by the Research Councils. We are delighted to welcome them as a supply partner and look forward to building a mutually beneficial relationship with them.”
This agreement is one of a series that has seen CRB continuing to grow through the wider economic difficulties of the last two years by increasing market share in existing territories and penetrating new overseas markets with Europe and North America showing strong growth. In 2009 CRB was named as one of the partners in the BIOSCENT project, part of the European Seventh Framework Programme for research and technological development (FP7). CRB’s involvement in BIOSCENT is to provide peptide synthesis expertise and synthetic peptides to support the development of peptides within the field of heart stem cell research and using peptide-directed antibodies to identify novel cell signalling factors.